Defence Therapeutics Inc. is a publicly traded Canadian biotechnology company specializing in precision intracellular drug delivery to enhance cancer treatments. Its proprietary Accum platform improves the efficacy and safety of biological and biosimilar pharmaceuticals, particularly antibody drug conjugates, radiopharmaceuticals, and vaccines targeting cancer and infectious diseases. Key programs include the AccuTOX anti-cancer initiative for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X, a mesenchymal stem cell-based cancer vaccine; mRNA vaccination efforts; Accuvac for dendritic cell cancer vaccines; protein-based formulations against COVID and other infections; and a cervical cancer vaccine. The company advances these through internal research, strategic collaborations with radiopharmaceutical groups, and licensing opportunities for its technology to boost potency at lower doses while reducing toxicity. Founded in 2017 and headquartered in Vancouver, Canada, with operations in Montreal, Defence Therapeutics plays a pivotal role in the oncology sector by enabling more effective biologic therapies.